BACKGROUND: Diabetic patients also show hypercoagulability and platelet hyperaggregability, with increased levels of platelet activation-markers such as P-selectin (CD62P) and platelet-derived microparticles. We investigated the effects of losartan and simvastatin on circulating levels of platelet activation markers, microparticles, soluble selectins, and soluble cell adhesion molecules in hypertensive and hyperlipidemic patients with or without Type 2 diabetes. METHODS: The subjects included 25 normotensive healthy controls and 41 hypertensive patients. The 41 hypertensive patients were divided into three groups: group A had hypertension and hyperlipidemia (n = 11), group B had hypertension and Type 2 diabetes (n = 14), and group C had hypertension, hyperlipidemia, and diabetes (n = 16). Losartan was administered to all of the patients at a dose of 50 mg/day for 24 weeks. In addition, simvastatin was administered to the hyperlipidemic patients at a dose of 10 mg/day for 24 weeks. RESULTS: There were significant differences in the levels of CD62P, CD63, PAC-1, platelet microparticles, endothelial microparticles, sE-selectin, and sVCAM-1 between the hypertensive patients and healthy controls. These markers were all significantly increased in hypertensive and hyperlipidemic patients with Type 2 diabetes. In hypertensive patients with diabetes, CD62P, CD63, PAC-1, platelet and endothelial microparticles, and soluble adhesion markers were all decreased by losartan monotherapy. The decrease of each marker in hypertensive and hyperlipidemic patients given combined therapy with losartan plus simvastatin was greater among those with than without Type 2 diabetes. Low-density lipoprotein was decreased significantly by simvastatin and was correlated with CD62P or platelet microparticles in all of the patients. CONCLUSION: Administration of losartan plus simvastatin to hypertensive and hyperlipidemic patients with Type 2 diabetes may prevent the development of cardiovascular complications caused by activated platelets and microparticles via another mechanism in addition to reduction of the blood pressure or lipid levels.
BACKGROUND:Diabeticpatients also show hypercoagulability and platelet hyperaggregability, with increased levels of platelet activation-markers such as P-selectin (CD62P) and platelet-derived microparticles. We investigated the effects of losartan and simvastatin on circulating levels of platelet activation markers, microparticles, soluble selectins, and soluble cell adhesion molecules in hypertensive and hyperlipidemic patients with or without Type 2 diabetes. METHODS: The subjects included 25 normotensive healthy controls and 41 hypertensivepatients. The 41 hypertensivepatients were divided into three groups: group A had hypertension and hyperlipidemia (n = 11), group B had hypertension and Type 2 diabetes (n = 14), and group C had hypertension, hyperlipidemia, and diabetes (n = 16). Losartan was administered to all of the patients at a dose of 50 mg/day for 24 weeks. In addition, simvastatin was administered to the hyperlipidemic patients at a dose of 10 mg/day for 24 weeks. RESULTS: There were significant differences in the levels of CD62P, CD63, PAC-1, platelet microparticles, endothelial microparticles, sE-selectin, and sVCAM-1 between the hypertensivepatients and healthy controls. These markers were all significantly increased in hypertensive and hyperlipidemic patients with Type 2 diabetes. In hypertensivepatients with diabetes, CD62P, CD63, PAC-1, platelet and endothelial microparticles, and soluble adhesion markers were all decreased by losartan monotherapy. The decrease of each marker in hypertensive and hyperlipidemic patients given combined therapy with losartan plus simvastatin was greater among those with than without Type 2 diabetes. Low-density lipoprotein was decreased significantly by simvastatin and was correlated with CD62P or platelet microparticles in all of the patients. CONCLUSION: Administration of losartan plus simvastatin to hypertensive and hyperlipidemic patients with Type 2 diabetes may prevent the development of cardiovascular complications caused by activated platelets and microparticles via another mechanism in addition to reduction of the blood pressure or lipid levels.
Authors: V Combes; A C Simon; G E Grau; D Arnoux; L Camoin; F Sabatier; M Mutin; M Sanmarco; J Sampol; F Dignat-George Journal: J Clin Invest Date: 1999-07 Impact factor: 14.808
Authors: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn Journal: Lancet Date: 2002-03-23 Impact factor: 79.321
Authors: Christine Krämer; Julia Sunkomat; Jana Witte; Maren Luchtefeld; Michael Walden; Boris Schmidt; Dimitrios Tsikas; Rainer H Böger; Wolf-Georg Forssmann; Helmut Drexler; Bernhard Schieffer Journal: Circ Res Date: 2002-04-19 Impact factor: 17.367
Authors: T Murakami; Y Komiyama; M Masuda; H Kido; S Nomura; S Fukuhara; M Karakawa; T Iwasaka; H Takahashi Journal: Eur J Clin Invest Date: 1996-11 Impact factor: 4.686
Authors: A Remuzzi; N Perico; C S Amuchastegui; B Malanchini; M Mazerska; C Battaglia; T Bertani; G Remuzzi Journal: J Am Soc Nephrol Date: 1993-07 Impact factor: 10.121
Authors: Abdolreza Rezaie-Majd; Thomas Maca; Robert A Bucek; Peter Valent; Michael R Müller; Peter Husslein; Ahmad Kashanipour; Erich Minar; Mehrdad Baghestanian Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Carmine Savoia; Lidia Sada; Luigi Zezza; Lorenzo Pucci; Francesco Maria Lauri; Alberto Befani; Alessandro Alonzo; Massimo Volpe Journal: Int J Hypertens Date: 2011-09-11 Impact factor: 2.420
Authors: L M Camargo; C N França; M C Izar; H T Bianco; L S Lins; S P Barbosa; L F Pinheiro; F A H Fonseca Journal: Braz J Med Biol Res Date: 2014-05-02 Impact factor: 2.590